Q2 sales and earnings beat estimatesInvestor concerns on pipeline, Zantac claimsraised its full-year profit and sales guidance on Wednesday after its second-quarter earnings beat expectations, helped by strong sales of its shingles vaccine Shingrix and HIV medicines.
The company now expects sales to increase by 8% to 10% this year, compared with 6% to 8% previously and for adjusted operating profit to increase between 11 to 13%, up from 10% to 12%. The better-than-expected results may further help revive investor confidence in Walmsley's strategy, coming a year after the company spun off its consumer health business, Haleon, in its most radical shake-up in 20 years.about the strength of its pipeline of drugs in development and costly U.S. litigation over discontinued heartburn drug Zantac.
Analysts were expecting a profit of 34.7 pence per share on sales of about 6.77 billion pounds, according to company-compiled consensus estimates.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »